Pulmatrix Inc (PULM)

$3.12 +0.28 (9.70%)
Market Cap 10.38M
Revenue (ttm) 7.81M
Net Income (ttm) -9.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -122.41%
Debt to Equity Ratio 0.00
Volume 52,800
Avg Vol 22,416
Day's Range N/A - N/A
Shares Out 3.65M
Stochastic %K 83%
Beta 1.72
Analysts Strong Buy
Price Target $10.00

Company Profile

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clin...

Industry: Biotechnology
Sector: Healthcare
Phone: 888 355 4440
Address:
945 Concord Street, Suite 1217, Framingham, United States
TinyTiger19
TinyTiger19 Feb. 23 at 11:52 PM
{}@SqueezeSharkie on a different level better than 90% of the traders on this platform. If you’re not tuned in, that’s a miss, make sure to follow him doesn’t cost you anything but a simple click.💎 $PZG $PULM $ETHD $HOOZ •,•
0 · Reply
HomeRunHitterXXXXX
HomeRunHitterXXXXX Feb. 23 at 8:30 PM
$PULM why this up?
1 · Reply
ghcolleen88
ghcolleen88 Feb. 23 at 7:03 PM
$PULM not really a chart guy but seems like the first step is to fill that gap to 4.60
0 · Reply
ghcolleen88
ghcolleen88 Feb. 23 at 6:47 PM
$PULM Volume clicking up
0 · Reply
_EmproX
_EmproX Feb. 23 at 4:04 PM
$ISPR $PULM $RDAC.X $ATLN ~
0 · Reply
tilli5285
tilli5285 Feb. 23 at 3:59 PM
$PULM someone knows something
2 · Reply
_EmproX
_EmproX Feb. 23 at 3:48 PM
$IKT $BNAI $JCSE $PULM <><>
0 · Reply
ghcolleen88
ghcolleen88 Feb. 23 at 3:46 PM
$PULM @Nakom
1 · Reply
ghcolleen88
ghcolleen88 Feb. 23 at 3:38 PM
$PULM wait til the news comes out the volume will really kick in !!!
0 · Reply
ghcolleen88
ghcolleen88 Feb. 23 at 3:02 PM
$PULM here we go !!!!!
0 · Reply
Latest News on PULM
Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives

Dec 18, 2025, 8:05 AM EST - 2 months ago

Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives

Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

Oct 16, 2025, 8:05 AM EDT - 4 months ago

Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

Aug 6, 2025, 8:05 AM EDT - 7 months ago

Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

May 15, 2025, 8:05 AM EDT - 10 months ago

Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM

May 9, 2025, 4:00 PM EDT - 10 months ago

PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

Mar 21, 2025, 8:05 AM EDT - 1 year ago

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

Nov 15, 2024, 8:00 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

GRDX

Pulmatrix and Cullgen Announce Proposed Merger

Nov 13, 2024, 9:00 AM EST - 1 year ago

Pulmatrix and Cullgen Announce Proposed Merger

Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 8, 2024, 10:26 AM EST - 1 year ago

Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 9:05 AM EDT - 1 year ago

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

May 29, 2024, 8:45 AM EDT - 1 year ago

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

MNKD

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)

May 15, 2024, 9:35 AM EDT - 1 year ago

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 10, 2024, 8:05 AM EDT - 1 year ago

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

Mar 28, 2024, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

Jan 8, 2024, 9:00 AM EST - 2 years ago

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 9, 2023, 9:05 AM EST - 2 years ago

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

Sep 19, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Aug 23, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 10, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Jul 11, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

Jun 15, 2023, 9:20 AM EDT - 2 years ago

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

May 24, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 12, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

Pulmatrix Supports World Asthma Day 2023

May 2, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Supports World Asthma Day 2023

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

Mar 30, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Feb 6, 2023, 9:10 AM EST - 3 years ago

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"

Jan 25, 2023, 9:05 AM EST - 3 years ago

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"

Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology

Jan 23, 2023, 9:05 AM EST - 3 years ago

Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Jan 4, 2023, 9:05 AM EST - 3 years ago

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 10, 2022, 9:05 AM EST - 3 years ago

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

Sep 26, 2022, 9:00 AM EDT - 3 years ago

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 8, 2022, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

Jul 12, 2022, 9:00 AM EDT - 3 years ago

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

May 12, 2022, 9:05 AM EDT - 4 years ago

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

Mar 29, 2022, 9:05 AM EDT - 4 years ago

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic Results

Mar 21, 2022, 12:45 PM EDT - 4 years ago

Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic Results

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

Mar 21, 2022, 8:05 AM EDT - 4 years ago

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

Mar 17, 2022, 4:05 PM EDT - 4 years ago

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline

Mar 1, 2022, 9:00 AM EST - 4 years ago

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split

Feb 24, 2022, 4:05 PM EST - 4 years ago

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split

Pulmatrix Issues Letter to Stockholders

Feb 1, 2022, 9:00 AM EST - 4 years ago

Pulmatrix Issues Letter to Stockholders

Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering

Dec 17, 2021, 4:30 PM EST - 4 years ago

Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering

Pulmatrix Announces $6.75 Million Registered Direct Offering

Dec 15, 2021, 8:00 AM EST - 4 years ago

Pulmatrix Announces $6.75 Million Registered Direct Offering

Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update

Nov 10, 2021, 4:15 PM EST - 4 years ago

Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update

Pulmatrix Announces Resolution of Contract Dispute with Cipla

Nov 9, 2021, 9:00 AM EST - 4 years ago

Pulmatrix Announces Resolution of Contract Dispute with Cipla

Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update

Aug 10, 2021, 9:10 AM EDT - 4 years ago

Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update

Pulmatrix appoints Director Anand Varadan

Jul 27, 2021, 10:00 AM EDT - 4 years ago

Pulmatrix appoints Director Anand Varadan

TinyTiger19
TinyTiger19 Feb. 23 at 11:52 PM
{}@SqueezeSharkie on a different level better than 90% of the traders on this platform. If you’re not tuned in, that’s a miss, make sure to follow him doesn’t cost you anything but a simple click.💎 $PZG $PULM $ETHD $HOOZ •,•
0 · Reply
HomeRunHitterXXXXX
HomeRunHitterXXXXX Feb. 23 at 8:30 PM
$PULM why this up?
1 · Reply
ghcolleen88
ghcolleen88 Feb. 23 at 7:03 PM
$PULM not really a chart guy but seems like the first step is to fill that gap to 4.60
0 · Reply
ghcolleen88
ghcolleen88 Feb. 23 at 6:47 PM
$PULM Volume clicking up
0 · Reply
_EmproX
_EmproX Feb. 23 at 4:04 PM
$ISPR $PULM $RDAC.X $ATLN ~
0 · Reply
tilli5285
tilli5285 Feb. 23 at 3:59 PM
$PULM someone knows something
2 · Reply
_EmproX
_EmproX Feb. 23 at 3:48 PM
$IKT $BNAI $JCSE $PULM <><>
0 · Reply
ghcolleen88
ghcolleen88 Feb. 23 at 3:46 PM
$PULM @Nakom
1 · Reply
ghcolleen88
ghcolleen88 Feb. 23 at 3:38 PM
$PULM wait til the news comes out the volume will really kick in !!!
0 · Reply
ghcolleen88
ghcolleen88 Feb. 23 at 3:02 PM
$PULM here we go !!!!!
0 · Reply
Love_To_Learn
Love_To_Learn Feb. 23 at 12:26 PM
$NCI $SLS $PULM
0 · Reply
fillzane
fillzane Feb. 20 at 3:54 PM
$PULM Pulmatrix develops inhaled therapies for respiratory diseases. Clinical validation drives valuation. Early-stage risk remains high.
0 · Reply
FoxySprout
FoxySprout Feb. 20 at 1:32 PM
$PULM
0 · Reply
HomeRunHitterXXXXX
HomeRunHitterXXXXX Feb. 19 at 9:23 PM
$PULM where is brokedick mo hiding he usually clams that he is bringing it up 😜
0 · Reply
Nakom
Nakom Feb. 19 at 3:20 PM
$PULM All good here in Pulmatrix land.
1 · Reply
Nakom
Nakom Feb. 18 at 6:55 PM
$PULM I wonder if these are a bunch of small trades or big block trades.
1 · Reply
ghcolleen88
ghcolleen88 Feb. 18 at 6:45 PM
$PULM volume is picking up when this goes it going to move fast.
0 · Reply
Gugger
Gugger Feb. 18 at 3:43 PM
$PULM already a daily volume ... 🤷‍♂️
1 · Reply
ghcolleen88
ghcolleen88 Feb. 18 at 3:17 PM
$PULM jmo something is being leaked. i’m going with mnkd to announce next thursday buying here !!!
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 17 at 6:58 PM
$PULM Current Stock Price: $2.50
0 · Reply
Gugger
Gugger Feb. 17 at 5:06 PM
$PULM Added some more, very low risk 😉
1 · Reply
Nakom
Nakom Feb. 17 at 4:02 PM
$PULM Who will get the Isperse technology. Will it be Teva, Boehringer Ingelheim, Novartis, Cipla, Mannkind, Viatris, Arrogrn, Aptar Pharma or possibly Merck. We shell see very soon. super Bullish!!!
0 · Reply